Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation.

Abstract

Glucuronidation and sulfation are phase 2 metabolic reactions catalyzed by large families of different isoenzymes in man. The textbook view that glucuronidation and sulfation lead to the production of harmless conjugates for simple excretion is not valid. Biologically active and toxic sulfates and glucuronides are produced and lead to adverse drug reactions, including immune hypersensitivity. Considerable variation in xenobiotic conjugation is observed as a result of altered expression of UDP-glucuronosyltransferases (UGTs) and sulfotransferases (STs). Recent cloning and expression of human cDNA encoding UGTs and STs has facilitated characterization of isoform substrate specificity, which has been further validated using specific antibodies and human tissue fractions. The availability of cloned/expressed human enzymes and specific antibodies has enabled the investigation of xenobiotic induction and metabolic disruption leading to adverse responses. Genetic polymorphisms of glucuronidation and sulfation are known to exist although the characterization and assessment of the importance of these variations are hampered by appropriate ethical studies in man with suitable safe model compounds. Genetic analysis has allowed molecular identification of defects in well-known hyperbilirubinemias. However, full characterization of the specific functional roles of human UGTs and STs requires rigorous kinetic and molecular analyses of the role of each enzyme in vivo through the use of specific antibodies and inhibitors. This will lead to the better prediction of variation of xenobiotic glucuronidation and sulfation in man. Environ Health Perspect 1 05(Suppl 4): 739-747 (1997)

Elucidation of (−)-epicatechin metabolites after ingestion of chocolate by healthy humans

“…Nevertheless, metabolite profile distribution might be modified depending on the amount of ( À )-epicatechin ingested. It has been demonstrated that sulfotransferases comprise a low-capacity system, whereas uridine-5 0 -diphosphate glucuronosyl-transferases have a higher capacity [36]. Therefore, it could be inferred that the ingestion of a higher amount of ( À )-epicatechin would result in higher relative concentration of ( À )-epicatechin glucuronides and even O-methyl glucuronides.…”

Synthetic Pot: Not Your Grandfather’s Marijuana

“…It is recognized that oxidative metabolism (Phase I) generally terminates the activity of the parent compounds and functionalizes them for future conjugation reactions (Phase II) such as glucuronidation and sulfation [153], considered the final step for terminating biological activity. Δ 9 -THC metabolism has been well studied and is extensively metabolized by cytochrome P450 enzymes CYP2C9 and CYP3A4, but only to a single major active metabolite (11-OH-Δ 9 -THC) with equivalent CB 1 cannabinoid receptor affinity [154] and slightly higher potency in antinociceptive assays [155] as compared to the parent drug.…”

Update on the Pharmacokinetics and Redox Properties of Protein-Bound Uremic Toxins

“…Therefore, rOat3 and rOatp2 are involved in CMPF efflux across the BBB. 23 conclusion that the majority of p-cresol, which is biosynthesized from dietary tyrosine and phenylalanine, undergoes sulfate conjugation by a sulfotransferase enzyme during its passage through the intestinal membrane, resulting in the production of a conjugate, namely PCS, 81 which, rather than p-cresol itself, circulates in the blood. 46,82,83 PCS is incompletely removed by hemodialysis because about 90% is bound to albumin.…”